Bayram Cengiz, Yaralı Neşe, Fettah Ali, Demirel Fatma, Tavil Betül, Kara Abdurrahman, Tunç Bahattin
Ankara Children’s Hematology and Oncology Hospital, Clinic of Pediatric Hematology, Ankara, Turkey Phone: +90 505 839 60 92 E-mail:
Turk J Haematol. 2017 Mar 1;34(1):40-45. doi: 10.4274/tjh.2015.0332. Epub 2016 Apr 18.
Improvement in long-term survival in patients with acute lymphoblastic leukemia (ALL) in childhood has led to the need for monitorization of treatment-related morbidity and mortality. In the current study, we aimed to evaluate endocrine side effects of treatment in ALL survivors who were in remission for at least 2 years.
Sixty patients diagnosed with ALL, who were in remission for at least 2 years, were cross-sectionally evaluated for long-term endocrine complications.
The median age of the patients at the time of diagnosis, at the time of chemotherapy completion, and at the time of the study was 5 years (minimum-maximum: 1.7-13), 8 years (minimum-maximum: 4.25-16), and 11.7 years (minimum-maximum: 7-22), respectively, and median follow-up time was 4 years (minimum-maximum: 2-10.1). At least one complication was observed in 81.6% of patients. Vitamin D insufficiency/deficiency (46.6%), overweight/obesity (33.3%), and dyslipidemia (23.3%) were the three most frequent endocrine complications. Other complications seen in our patients were hyperparathyroidism secondary to vitamin D deficiency (15%), insulin resistance (11.7%), hypertension (8.3%), short stature (6.7%), thyroid function abnormality (5%), precocious puberty (3.3%), and decreased bone mineral density (1.7%). There were no statistically significant correlations between endocrine complications and age, sex, and radiotherapy, except vitamin D insufficiency/deficiency, which was significantly more frequent in pubertal ALL survivors compared to prepubertal ALL survivors (57.5% and 25%, respectively, p=0.011).
A high frequency of endocrine complications was observed in the current study. The high frequency of late effects necessitates long-term surveillance of this population to better understand the incidence of late-occurring events and the defining of high-risk features that can facilitate developing intervention strategies for early detection and prevention.
儿童急性淋巴细胞白血病(ALL)患者长期生存率的提高,使得有必要对治疗相关的发病率和死亡率进行监测。在本研究中,我们旨在评估缓解至少2年的ALL幸存者的治疗内分泌副作用。
对60例诊断为ALL且缓解至少2年的患者进行长期内分泌并发症的横断面评估。
患者诊断时、化疗完成时及研究时的中位年龄分别为5岁(最小-最大:1.7 - 13岁)、8岁(最小-最大:4.25 - 16岁)和11.7岁(最小-最大:7 - 22岁),中位随访时间为4年(最小-最大:2 - 10.1年)。81.6%的患者至少观察到一种并发症。维生素D不足/缺乏(46.6%)、超重/肥胖(33.3%)和血脂异常(23.3%)是三种最常见的内分泌并发症。我们患者中观察到的其他并发症包括维生素D缺乏继发的甲状旁腺功能亢进(15%)、胰岛素抵抗(11.7%)、高血压(8.3%)、身材矮小(6.7%)、甲状腺功能异常(5%)、性早熟(3.3%)和骨密度降低(1.7%)。除维生素D不足/缺乏外,内分泌并发症与年龄、性别和放疗之间无统计学显著相关性,青春期ALL幸存者中维生素D不足/缺乏的发生率显著高于青春期前ALL幸存者(分别为57.5%和25%,p = 0.011)。
本研究中观察到内分泌并发症的高发生率。晚期效应的高发生率需要对该人群进行长期监测,以更好地了解晚期事件的发生率,并确定可促进制定早期检测和预防干预策略的高危特征。